‘Time will tell whether that was a good bet’: My adviser got me a full SpaceX IPO allocation. Was I lucky?
Getting a “full fill” in a blockbuster IPO is rare for most individuals. When the name is SpaceX—or a carve‑out like Starlink—the surprise turns into a question: was this a stroke of luck, a sign the deal wasn’t as hot as believed, or simply the result of how allocations actually work? The honest answer is: some of each. Here’s how to think about what happened, what it might signal, and how to judge whether it was a good bet over time.
First, sanity‑check what you actually received
– Confirm the deal. Was it SpaceX itself, a Starlink spin‑off, a secondary sale by existing holders, or a private pre‑IPO vehicle? True IPO shares should be traceable to a filed prospectus (S‑1/F‑1) and a ticker listing on a major exchange at pricing.
– Verify the paperwork. You should have an allocation confirmation from your broker after pricing, a trade confirmation on listing day, and a CUSIP. Be wary of “guaranteed allocations” in advance of pricing, wires to non‑broker accounts, or anything not backed by an official prospectus.
– Check restrictions. Are your shares subject to any flipping restrictions, penalty bids, or lock‑ups beyond standard market practice? Read the new‑issue disclosures from your brokerage.
How IPO allocations really work
– Bookbuilding basics. Underwriters build an order book from institutions, wealth‑management channels, and (sometimes) retail. If demand exceeds supply at the indicated price range, orders are scaled back. If demand is soft, investors often receive what they asked for—or more.
– Hot vs. cold deals. In a genuinely “hot” deal, large institutions and top‑tier private‑bank clients are prioritized. Retail through online broker channels typically gets a fraction. In “cold” or just “warm” deals, full allocations are common because underwriters want to ensure a stable aftermarket.
– Priority matters. Clients who (a) are large, long‑term “sticky” holders, (b) participate consistently in new issues without flipping, and (c) have relationships with the underwriting firm often get better fills. Early, price‑insensitive indications can help.
– Directed share programs. Some IPOs reserve shares for employees, customers, or partners; these can produce full fills for eligible participants even if the broader book is oversubscribed.
So, were you lucky?
Possibly—but “full allocation” alone isn’t proof of a lottery win. It could mean:
– You’re a priority client at a firm with meaningful allocation.
– You fit the issuer’s desire for stable holders.
– The deal, at least in your distribution channel, wasn’t as oversubscribed as headlines suggested.
– It wasn’t actually the most in‑demand slice (e.g., a secondary sale by existing holders, or a SPV with extra fees/lock‑ups).
What history says about IPO outcomes
– The “pop” vs. the marathon. Many IPOs show a first‑day “pop” due to underpricing. Longer‑term, academic work (e.g., Jay Ritter’s research) finds average underperformance over 3–5 years for typical IPO cohorts, though dispersion is large and quality franchises can buck the trend.
– Supply overhang. When lock‑ups expire (often ~180 days), newly freed shares can pressure prices. The end of underwriter stabilization (greenshoe period, often 30 days) also removes a near‑term support.
– Size and maturity. Mega‑cap or well‑known issuers often see smaller first‑day pops but can offer steadier fundamentals; earlier‑stage, story‑driven names are more volatile post‑IPO.
What’s unique about SpaceX/Starlink to consider
– Capital intensity and cadence. Reusable rockets help, but launch and constellation businesses remain capex‑heavy. Starlink replenishment cycles, manufacturing scale, and launch cadence drive cash needs.
– Revenue mix and margins. Launch services, government/DoD contracts, commercial customers, and consumer broadband have very different margin structures and cyclicality.
– Unit economics for Starlink. ARPU, churn, terminal hardware subsidies, business/enterprise penetration, and international regulatory approvals matter more to value than raw subscriber counts.
– Competitive and regulatory risk. ULA, Blue Origin, international entrants, spectrum issues, debris/space traffic management, and geopolitical exposure can swing outcomes.
– Key‑person and governance. Dual‑class shares, related‑party transactions, and key‑man dependence can elevate governance risk and valuation dispersion.
– Valuation at entry. Whether your bet was “good” depends heavily on the multiple you paid versus realistic cash‑flow trajectories, not on the brand or the story.
Signals your full allocation might carry
– Positive signals:
– Your broker prioritized you as a sticky, long‑term holder.
– You placed an early, range‑topping indication without conditions.
– The syndicate wanted broad placement to reduce volatility.
– Cautionary signals:
– The book wasn’t as tight as rumored; pricing leaned to the top (or above) of the range without meaningful oversubscription.
– You were offered additional shares after initial allocations—often a sign supply needed a home.
– Your allocation came through a structure with extra fees, performance waterfalls, or extended lock‑ups relative to the IPO.
How to judge, from here, whether it was a good bet
– Define success. Are you seeking a day‑one pop, a 12–24 month compounder, or a 5–10 year ownership stake? Different horizons produce different “good” outcomes.
– Track the thesis, not the tape. Identify 3–5 operating KPIs tied to your thesis (e.g., Starlink ARPU and churn, launch cadence and failure rate, gross margin trajectory, free cash flow inflection). Revisit quarterly.
– Respect supply calendars. Be deliberate around the greenshoe window and major lock‑up expiries; volatility often spikes.
– Size appropriately. A celebrated narrative can still produce drawdowns of 40–60%. If a drop at that scale imperils your plan, your position is too large.
– Avoid anchoring to the IPO price. The offer price is a syndicate decision, not intrinsic value. Re‑underwrite at each decision point based on updated information.
– Plan the exit. If you intended to harvest a pop, set a rules‑based sell discipline. If you’re long‑term, decide what would falsify your thesis ahead of time.
Questions to ask your adviser now
– How was my allocation sourced within the syndicate, and were there any selling concessions or fees charged to me?
– Am I subject to flipping restrictions or penalties if I sell within 30 days?
– How does this position fit my investment policy statement and risk profile? What was the base‑case, bear‑case, and bull‑case underwriting at the offer price?
– Are there any conflicts of interest in your firm’s new‑issue distribution that I should understand?
– What are the key milestones the firm will track to reassess the position?
Red flags to rule out
– No filed prospectus or exchange listing, but requests for funds “to secure” shares.
– Allocations conditioned on purchasing unrelated products or on aftermarket price support.
– Vague or shifting terms about lock‑ups, fees, or liquidity.
Bottom line
Yes, you might have been lucky—either because your relationship won you a scarce seat, or because the book wasn’t as tight as the hype suggested. But whether it was a good bet will be determined less by the thrill of getting a full allocation and more by two things you control: the price you effectively paid relative to realistic cash flows, and your discipline in managing the position against a clear thesis and timeline. Time will tell; your process will help it tell a better story.
